ASCO GI 2024 | Therapeutic challenges in HCC: individualizing treatment decisions

Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy, discusses the challenge of deciding appropriate therapies for hepatocellular carcinoma (HCC) in the absence of head-to-head comparisons among first-line treatment options. With two available combinations, durvalumab plus tremelimumab and atezolizumab plus bevacizumab, direct comparisons are difficult due to distinct efficacy and safety profiles. The lack of biomarkers further complicates decision-making. In clinical practice, clinicians must consider individual patient factors such as comorbidities, concomitant medications, and risk profiles, basing their treatment decisions on clinical characteristics and data from relevant trials. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.